Korean Drug Co., Ltd. (KOSDAQ: 014570)
South Korea
· Delayed Price · Currency is KRW 4,995.00
-45.00 (-0.89%)
Oct 11, 2024, 9:00 AM KST
Korean Drug Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -1,242 | -4,917 | 11,809 | 9,042 | 7,360 | 3,895 | Upgrade
|
| Depreciation & Amortization | 2,005 | 1,749 | 1,383 | 1,470 | 1,355 | 1,184 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1.12 | 3.68 | -2.81 | -1.13 | 5.28 | -58.65 | Upgrade
|
| Loss (Gain) From Sale of Investments | 165.3 | -132.87 | 383.6 | 359.46 | 1,534 | -737.9 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | 576.86 | 23.11 | Upgrade
|
| Provision & Write-off of Bad Debts | -350.51 | - | - | - | - | -72.65 | Upgrade
|
| Other Operating Activities | -7,042 | 2,118 | -801.33 | 1,384 | 1,491 | 602.69 | Upgrade
|
| Change in Accounts Receivable | 3,034 | 3,566 | -1,390 | -948.64 | 872.88 | 4,910 | Upgrade
|
| Change in Inventory | -6,245 | -4,657 | -971.78 | -2,149 | 1,030 | -2,461 | Upgrade
|
| Change in Accounts Payable | -1,177 | 1,916 | -3,208 | 550.5 | -403.67 | 402.34 | Upgrade
|
| Change in Other Net Operating Assets | 161.59 | -1,645 | -1,288 | -900.83 | -1,492 | -1,479 | Upgrade
|
| Operating Cash Flow | -10,691 | -1,999 | 5,913 | 8,806 | 12,330 | 6,209 | Upgrade
|
| Operating Cash Flow Growth | - | - | -32.86% | -28.58% | 98.60% | 7.27% | Upgrade
|
| Capital Expenditures | -3,138 | -5,814 | -6,093 | -1,146 | -738.47 | -3,052 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.12 | 1.12 | 5.86 | 4.5 | - | 43.38 | Upgrade
|
| Sale (Purchase) of Intangibles | -68.4 | -69.6 | -384.22 | 157.73 | 219.04 | -9.47 | Upgrade
|
| Investment in Securities | 11,161 | 18,159 | 894.66 | -6,980 | -9,911 | -1,161 | Upgrade
|
| Other Investing Activities | -0 | -0 | 175 | -291 | 140 | 0 | Upgrade
|
| Investing Cash Flow | 7,955 | 12,277 | -5,401 | -8,254 | -10,290 | -4,179 | Upgrade
|
| Long-Term Debt Repaid | - | -82.46 | -76.55 | -75.69 | -81.97 | -85.1 | Upgrade
|
| Total Debt Repaid | -81.56 | -82.46 | -76.55 | -75.69 | -81.97 | -85.1 | Upgrade
|
| Net Debt Issued (Repaid) | -81.56 | -82.46 | -76.55 | -75.69 | -81.97 | -85.1 | Upgrade
|
| Issuance of Common Stock | 32.05 | 18.31 | 3.61 | 24.01 | 10.01 | 4.41 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -1,103 | - | -83.11 | Upgrade
|
| Dividends Paid | -1,618 | -1,941 | -1,833 | -1,634 | -1,089 | -1,090 | Upgrade
|
| Other Financing Activities | -49.31 | -2.9 | 0 | 0 | - | - | Upgrade
|
| Financing Cash Flow | -1,717 | -2,008 | -1,906 | -2,789 | -1,161 | -1,254 | Upgrade
|
| Foreign Exchange Rate Adjustments | -12.98 | -7.09 | -20.35 | 10.95 | -81.16 | 15.82 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | - | -0 | 0 | Upgrade
|
| Net Cash Flow | -4,465 | 8,263 | -1,415 | -2,227 | 797.4 | 790.78 | Upgrade
|
| Free Cash Flow | -13,829 | -7,812 | -180.15 | 7,660 | 11,592 | 3,156 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -33.92% | 267.27% | -29.67% | Upgrade
|
| Free Cash Flow Margin | -17.75% | -9.60% | -0.23% | 10.29% | 17.36% | 5.68% | Upgrade
|
| Free Cash Flow Per Share | -1284.03 | -724.50 | -16.70 | 701.43 | 1066.29 | 289.26 | Upgrade
|
| Cash Interest Paid | 4.07 | 3.02 | 2.1 | 1.53 | 3.13 | - | Upgrade
|
| Cash Income Tax Paid | 11,966 | 12,140 | 3,383 | 2,274 | 840.74 | 896.06 | Upgrade
|
| Levered Free Cash Flow | -12,283 | 2,092 | -2,709 | 6,243 | 9,411 | 3,329 | Upgrade
|
| Unlevered Free Cash Flow | -12,280 | 2,094 | -2,707 | 6,244 | 9,413 | 3,331 | Upgrade
|
| Change in Net Working Capital | 12,124 | -2,029 | 6,569 | 1,279 | -1,678 | -3,074 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.